| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CUTTING EDGE |
*
Department of Experimental Transplantation and Immunology, Medicine Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD 20892;
Biomira USA, Cranbury, NJ 08512; and
SAIC-Frederick, Frederick, MD 21702
We developed a liposome carrier for a model nonimmunogenic, self Ag. This carrier reproducibly converted lymphoma Ig into a potent tumor rejection Ag in mice. A single immunization induced protection against challenges representing 20 to 100 times the minimum lethal dose of parental tumor. This protective effect required minimal amounts of incorporated Ag and IL-2 and elicited specific Abs (compared with free Ag or liposomal control Ig which did not elicit any specific Abs); depletion experiments demonstrated a requirement for effector CD4+ and CD8+ T cells. Head-to-head comparisons, indicating superior potency and induction of specific T cell activation, distinguished liposomal from prototype, carrier-conjugated Ag. These results provide a strategy for formulating weak tumor or other clinically important Ags into vaccines.
This article has been cited by other articles:
|
|
 |
|
  M. C. Popescu, R. J. Robb, M. M. Batenjany, L. T. Boni, M. E. Neville, R. W. Pennington, S. S. Neelapu, and L. W. Kwak A novel proteoliposomal vaccine elicits potent antitumor immunity in mice Blood, June 15, 2007; 109(12): 5407 - 5410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kitano, S. Kageyama, Y. Nagata, Y. Miyahara, A. Hiasa, H. Naota, S. Okumura, H. Imai, T. Shiraishi, M. Masuya, et al. HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan Clin. Cancer Res., December 15, 2006; 12(24): 7397 - 7405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Neelapu, S. Baskar, B. L. Gause, C. B. Kobrin, T. M. Watson, A. R. Frye, R. Pennington, L. Harvey, E. S. Jaffe, R. J. Robb, et al. Human Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma Antigen Clin. Cancer Res., December 15, 2004; 10(24): 8309 - 8317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. U. Lundin, P. O. Hofgaard, H. Omholt, L. A. Munthe, A. Corthay, and B. Bogen Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies Blood, July 15, 2003; 102(2): 605 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-W. Chen, Y.-P. Lee, Y.-F. Chung, Y.-C. Shih, J.-P. Tsai, M.-H. Tao, and C.-C. Ting Inducing long-term survival with lasting anti-tumor immunity in treating B cell lymphoma by a combined dendritic cell-based and hydrodynamic plasmid-encoding IL-12 gene therapy Int. Immunol., March 1, 2003; 15(3): 427 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Timmerman and R. Levy Linkage of Foreign Carrier Protein to a Self-Tumor Antigen Enhances the Immunogenicity of a Pulsed Dendritic Cell Vaccine J. Immunol., May 1, 2000; 164(9): 4797 - 4803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Karanikas, J. Lodding, V. C. Maino, and I. F. C. McKenzie Flow Cytometric Measurement of Intracellular Cytokines Detects Immune Responses in MUC1 Immunotherapy Clin. Cancer Res., March 1, 2000; 6(3): 829 - 837. [Abstract] [Full Text]
|
|
|
|
|
|
A. D. Syrengelas and R. Levy DNA Vaccination Against the Idiotype of a Murine B Cell Lymphoma: Mechanism of Tumor Protection J. Immunol., April 15, 1999; 162(8): 4790 - 4795. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
